Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy

Patients with high‐grade soft tissue sarcomas are at high risk of developing local disease recurrence and metastatic disease. [F‐18]‐fluorodeoxy‐D‐glucose (FDG) positron emission tomography (PET) scans are hypothesized to detect histopathologic response to therapy and to predict risk of tumor progression in patients with various malignancies. Serial FDG‐PET scans were taken to determine the correlation between FDG uptake and patient outcomes in patients receiving multimodality treatment of extremity sarcomas.

[1]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[2]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[4]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[5]  J. Eary,et al.  FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma , 2003, Skeletal Radiology.

[6]  T. Delaney,et al.  Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. , 2001, International journal of radiation oncology, biology, physics.

[7]  K. Hess,et al.  Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas , 2002, Cancer.

[8]  W. Hiddemann,et al.  Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. O’Sullivan,et al.  Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  J. Eary,et al.  Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography , 2002, Cancer.

[11]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[12]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Wood,et al.  Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Folpe,et al.  (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M Schwaiger,et al.  Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  J. Neglia,et al.  Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide. , 1998, European journal of cancer.

[21]  R. Benjamin,et al.  Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. , 1998, American journal of clinical oncology.

[22]  D. Mankoff,et al.  Tumor metabolic rates in sarcoma using FDG PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Sylvester,et al.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997 .

[25]  D. Crowther.  Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data , 1997, The Lancet.

[26]  Su-Chun Cheng,et al.  Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Lowe,et al.  Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F‐18]fluorodeoxyglucose positron emission tomography , 1997, Head & neck.

[28]  D. Winchester,et al.  The National Cancer Data Base report on soft tissue sarcoma , 1996, Cancer.

[29]  H C Charles,et al.  Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  D H Leung,et al.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Benjamin,et al.  Preoperative Chemotherapy for Soft‐tissue Sarcomas of the Extremities , 1990, Annals of surgery.

[32]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[33]  J. Coindre,et al.  Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.

[34]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .